Literature DB >> 19388135

Host cell proteins in biologics development: Identification, quantitation and risk assessment.

Xing Wang1, Alan K Hunter, Ned M Mozier.   

Abstract

Host cell proteins (HCPs) are those produced or encoded by the organisms and unrelated to the intended recombinant product. Some are necessary for growth, survival, and normal cellular processing whereas others may be non-essential, simply carried along as baggage. Like the recombinant product, HCPs may also be modified by the host with a number of post-translational modifications. Regardless of the utility, or lack thereof, HCPs are undesirable in the final drug substance. Though commonly present in small quantities (parts per million expressed as nanograms per milligrams of the intended recombinant protein) much effort and cost is expended by industry to remove them. The purpose of this review is to summarize what is of relevance in regards to the biology, the impact of genomics and proteomics on HCP evaluation, the regulatory expectations, analytical approaches, and various methodologies to remove HCPs with bioprocessing. Historical data, bioinformatics approaches and industrial case study examples are provided. Finally, a proposal for a risk assessment tool is provided which brings these facets together and proposes a means for manufacturers to classify and organize a control strategy leading to meaningful product specifications. 2009 Wiley Periodicals, Inc.

Mesh:

Substances:

Year:  2009        PMID: 19388135     DOI: 10.1002/bit.22304

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  34 in total

1.  Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography/mass spectrometry.

Authors:  Catalin E Doneanu; Alex Xenopoulos; Keith Fadgen; Jim Murphy; St John Skilton; Holly Prentice; Martha Stapels; Weibin Chen
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

2.  Toward the complete characterization of host cell proteins in biotherapeutics via affinity depletions, LC-MS/MS, and multivariate analysis.

Authors:  James A Madsen; Victor Farutin; Theresa Carbeau; Steve Wudyka; Yan Yin; Stephen Smith; James Anderson; Ishan Capila
Journal:  MAbs       Date:  2015-08-20       Impact factor: 5.857

3.  Specific Immune Response to Phospholipase B-Like 2 Protein, a Host Cell Impurity in Lebrikizumab Clinical Material.

Authors:  Saloumeh Kadkhodayan Fischer; Melissa Cheu; Kun Peng; John Lowe; James Araujo; Elaine Murray; Dana McClintock; John Matthews; Patricia Siguenza; An Song
Journal:  AAPS J       Date:  2016-10-13       Impact factor: 4.009

4.  Host cell protein dynamics in recombinant CHO cells: impacts from harvest to purification and beyond.

Authors:  Catherine Em Hogwood; Daniel G Bracewell; C Mark Smales
Journal:  Bioengineered       Date:  2013-01-17       Impact factor: 3.269

5.  Knockout of a difficult-to-remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations.

Authors:  Josephine Chiu; Kristin N Valente; Nicholas E Levy; Lie Min; Abraham M Lenhoff; Kelvin H Lee
Journal:  Biotechnol Bioeng       Date:  2016-12-27       Impact factor: 4.530

6.  Elucidation of the CHO Super-Ome (CHO-SO) by Proteoinformatics.

Authors:  Amit Kumar; Deniz Baycin-Hizal; Daniel Wolozny; Lasse Ebdrup Pedersen; Nathan E Lewis; Kelley Heffner; Raghothama Chaerkady; Robert N Cole; Joseph Shiloach; Hui Zhang; Michael A Bowen; Michael J Betenbaugh
Journal:  J Proteome Res       Date:  2015-10-13       Impact factor: 4.466

7.  Capillary zone electrophoresis tandem mass spectrometry detects low concentration host cell impurities in monoclonal antibodies.

Authors:  Guijie Zhu; Liangliang Sun; Jennifer Heidbrink-Thompson; Srilatha Kuntumalla; Hung-yu Lin; Christopher J Larkin; James B McGivney; Norman J Dovichi
Journal:  Electrophoresis       Date:  2016-02       Impact factor: 3.535

Review 8.  Quality Control and Downstream Processing of Therapeutic Enzymes.

Authors:  David Gervais
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

9.  Cell-based influenza vaccine: current production, halal status assessment, and recommendations towards Islamic-compliant manufacturing.

Authors:  Nurul Nadiah Zulkarnain; Nurina Anuar; Norliza Abd Rahman; Siti Rozaimah Sheikh Abdullah; Muhammad Nazir Alias; Mashitoh Yaacob; Zhongren Ma; Gongtao Ding
Journal:  Hum Vaccin Immunother       Date:  2021-02-04       Impact factor: 3.452

10.  Of [Hamsters] and men: a new perspective on host cell proteins.

Authors:  Andres H Gutiérrez; Leonard Moise; Annie S De Groot
Journal:  Hum Vaccin Immunother       Date:  2012-09-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.